Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval

The appropriate interval between heterologous prime adenoviral vectored vaccination and boost mRNA vaccination remains unclear. We recruited 100 adult participants to receive a prime adenoviral vectored vaccine (ChAdOx1, AstraZeneca) and a boost mRNA vaccine (mRNA-1273, Moderna) 12 weeks apart and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Wang-Huei, Chang, Sui-Yuan, Hsieh, Ming-Ju, Ieong, Si-Man, Chang, Shan-Chwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Formosan Medical Association. Published by Elsevier Taiwan LLC. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385402/
https://www.ncbi.nlm.nih.gov/pubmed/35987747
http://dx.doi.org/10.1016/j.jfma.2022.07.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385402/
https://www.ncbi.nlm.nih.gov/pubmed/35987747
http://dx.doi.org/10.1016/j.jfma.2022.07.010

Ejemplares similares